Joe Dysart MM&M - Medical Marketing and Media

Joe Dysart

Most recent articles by Joe Dysart

Therapeutic Focus: Cardiovascular

Therapeutic Focus: Cardiovascular

The cardiovascular space has long ranked among the pharma industry’s most vibrant. Even by that standard, however, 2015 is shaping up as a blockbuster year, and PCSK9 inhibitors have a lot to do with projections. Estimates for their success could prove even better if they are shown to reduce cardiovascular event risk, as well. Joe Dysart explains

Therapeutic Focus 2014: Neurology

Therapeutic Focus 2014:

New therapies are shaking up MS and insomnia, while the slow pace of progress in Alzheimer’s
continues to frustrate patients and physicians alike. Welcome to neurology, where, Joe Dysart
reports, treatment breakthroughs in certain areas are counteracted by setbacks in others

Therapeutic Focus 2014: Vaccines

Therapeutic Focus 2014: Vaccines

The anti-vaccination movement continues to make noise, but the Ebola scare has highlighted the role vaccines play in controlling diseases—and saving lives. Joe Dysart looks at the implications of the quest for an anti-Ebola vaccine, as well as the corporate shakeup in the vaccine sector.

Analysts haven't soured on Yervoy, despite miss in prostate cancer

Therapeutic Focus 2014: Oncology

Immunotherapy is an emerging powerhouse in cancer treatment. Early gains being made in multiple tumor types provide a glimpse of the effectiveness of several agents and regimens. While longer follow-up is needed, the results have analysts talking about a big shift in the war on cancer. Joe Dysart reports

Devices & Diagnostics: Diagnostic Companions

Devices & Diagnostics Report: Diagnostic Companions

Marketing a diagnostic and drug in tandem requires a new business model. Collaborators Abbott and Pfizer have found success by coordinating marketplace efforts and promoting their wares as a package deal. Theirs is a playbook others may emulate as companion diagnostics become more entrenched. Joe Dysart reports

Therapeutic Focus 2014: Rheumatology

Therapeutic Focus 2014: Rheumatology

Few autoimmune competitors even come close to commercial stalwarts Humira, Enbrel and Remicade. But as a host of high-science treatments emerge seeking to threaten their reign, an old-fashioned and heretofore illicit drug could beckon patients to look beyond traditional medicines for rheumatology relief. Joe Dysart surveys the sector

Therapeutic Focus 2014: Metabolic

Therapeutic Focus 2014: Metabolic

The launch front in this category is relatively calm—for now. A movement is brewing to unseat the top diabetes drug, a long-acting insulin, as faster-acting products emerge. Joe Dysart on the intrigue in the metabolic pipeline